Cystic Fibrosis Lung clinical trials

Explore recruiting cystic fibrosis lung clinical trials.

Recruiting cystic fibrosis lung studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cystic Fibrosis Lung trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)

Italy, Spain, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis

Poland, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A clinical trial to evaluate the long-term safety and durability of efficacy of BI 3720931, an inhaled lentiviral vector gene therapy, after single dose administration in a previous clinical trial in people with cystic fibrosis rolled-over from a previous clinical trial with BI 3720931 (LenticlairTM-ON).

Spain, France, Italy, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Cystic Fibrosis Lung trials by city

Cystic Fibrosis Lung in Toronto Cystic Fibrosis Lung in Vancouver Cystic Fibrosis Lung in Montreal Cystic Fibrosis Lung in Calgary Cystic Fibrosis Lung in Edmonton Cystic Fibrosis Lung in Ottawa Cystic Fibrosis Lung in Winnipeg Cystic Fibrosis Lung in Quebec City Cystic Fibrosis Lung in Hamilton Cystic Fibrosis Lung in Kitchener Cystic Fibrosis Lung in London Cystic Fibrosis Lung in Halifax Cystic Fibrosis Lung in New York Cystic Fibrosis Lung in Los Angeles Cystic Fibrosis Lung in Chicago Cystic Fibrosis Lung in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease